BOD

France ranks in top fifth globally as location for multinationals’ legal entities

Retrieved on: 
Thursday, October 26, 2023
Consulting, Legal, Professional Services, Finance, Online, Documentation, Beneficial ownership, BOD, Corporation, EPM, Sierra, Articles of association, Record, UBO, Workload, Security (finance), Medical device, Cryptocurrency, Citco, AOA, Mercator

France is ranked in the top 20% of jurisdictions globally as an attractive location for multinationals to base legal entities, according to data compiled by Entity Portfolio Management (EPM) leader Mercator® by Citco (Mercator) , in its France EPM: Special Report .

Key Points: 
  • France is ranked in the top 20% of jurisdictions globally as an attractive location for multinationals to base legal entities, according to data compiled by Entity Portfolio Management (EPM) leader Mercator® by Citco (Mercator) , in its France EPM: Special Report .
  • However, the data reveals the country is 4% more expensive for multinationals to operate in compared to the global average.
  • In comparison to higher-ranking jurisdictions, France requires physical paper filings and a local presence.
  • In the lack of a so-called real beneficiary, it is possible to report the management of the company as legal representative(s).

FAW Group and Mobileye Forge Strategic Alliance in Autonomous Driving

Retrieved on: 
Thursday, September 14, 2023
Technology, Mobile, Wireless, Automotive Manufacturing, Manufacturing, Automotive, Autonomous Driving, Vehicles, Artificial Intelligence, Environment, Software, Hardware, Semiconductor, Green Technology, Consumer Electronics, Satellite, FAW, Partnership, Supervision, FAW Group, CPC, Policy, Multimedia, Hongqi (marque), BOD, Love, AV, ADAS, Mobile phone, Automotive industry, Mobileye

FAW Group, one of the largest Chinese automotive groups, and Mobileye (Nasdaq: MBLY), a global leader in autonomous driving solutions, have announced a new strategic partnership leveraging their respective industry advantages in software, hardware and technology products.

Key Points: 
  • FAW Group, one of the largest Chinese automotive groups, and Mobileye (Nasdaq: MBLY), a global leader in autonomous driving solutions, have announced a new strategic partnership leveraging their respective industry advantages in software, hardware and technology products.
  • The two sides will work together to create new products based on Mobileye SuperVision™ and Mobileye Chauffeur™ platforms, to empower customers with safe, enjoyable driving experiences.
  • The two companies will start working together on FAW Hongqi brand vehicles, bringing the Mobileye SuperVision highly advanced automated driving assist platform to key models of the Hongqi brand.
  • That will be followed closely by work toward integrating the Mobileye Chauffeur “eyes-off, hands-off" driving technology for specified domains into the much-anticipated E701 vehicle.

AIM-HI Accelerator Fund Welcomes New Leadership and Members to Its Board of Directors

Retrieved on: 
Wednesday, September 6, 2023
Science, Health, Oncology, Research, United Nations Foundation, Chairperson, Cancer, Woman, MBA, Entrepreneurship, The Business Council, Sustainability Accounting Standards Board, National Foundation for Cancer Research, Scripps Research, Patient, Investment, BOD, NFCR, Disease, Pharmaceutical industry, Management

The AIM-HI Accelerator Fund, an emerging non-profit impact-investment organization committed to advancing early-stage, oncology companies, is pleased to announce an important update to its Board of Directors (BOD) leadership.

Key Points: 
  • The AIM-HI Accelerator Fund, an emerging non-profit impact-investment organization committed to advancing early-stage, oncology companies, is pleased to announce an important update to its Board of Directors (BOD) leadership.
  • These Board appointments bring in multidisciplinary expertise, enabling AIM-HI to leverage new partnerships and collaboration networks to foster continued innovation for cancer drug development.
  • We are grateful to NFCR for their steadfast support of the AIM-HI Accelerator Fund since its inception.
  • For more information about AIM-HI and its Board of Directors, please visit the AIM-HI website .

Former Pfizer Vaccine Executive Nanette Cocero Joins the PharmaJet Board of Directors

Retrieved on: 
Tuesday, July 11, 2023
Biotechnology, Medical Devices, Infectious Diseases, Health, Pharmaceutical, Vaccine, University, Internal medicine, Wharton School of the University of Pennsylvania, Marketing, COVID-19, MBA, Multimedia, Inflammation, COVID-19 vaccination in mainland China, BOD, Rare, Cornell University, Pharmaceutical industry, Chemistry, Pharmacology

PharmaJet ,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors.

Key Points: 
  • PharmaJet ,® a company engineering Precision Delivery Systems™ that overcome the challenges of vaccines and pharmaceuticals delivery, today announced that Nanette Cocero, Ph.D., has been appointed to its Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20230711997138/en/
    Nanette Cocero, former Pfizer Vaccine executive, joins the PharmaJet Board of Directors.
  • (Photo: Business Wire)
    “The addition of Dr. Cocero continues to build on the pharmaceutical expertise within PharmaJet.
  • With 25+ years of experience, Dr. Cocero was most recently the Global President of Pfizer Vaccines.

Eli Lilly Selects ABEC for World’s Largest Single-Use Biopharmaceutical Manufacturing Facility

Retrieved on: 
Monday, July 10, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Health Technology, Heart, Bioreactor, CSR, Plant, Lilly, BOD, Engineering, Fine chemical, ABEC

ABEC , a leader in engineered solutions and services for biotech manufacturing, announced it will deliver multiple Custom Single Run (CSR®) single-use systems to Eli Lilly’s next-generation biopharmaceutical manufacturing facility in Limerick, Ireland.

Key Points: 
  • ABEC , a leader in engineered solutions and services for biotech manufacturing, announced it will deliver multiple Custom Single Run (CSR®) single-use systems to Eli Lilly’s next-generation biopharmaceutical manufacturing facility in Limerick, Ireland.
  • ABEC’s large-scale CSR Bioreactors will be at the heart of the facility, and ABEC will also manufacture, test, and install large-scale CSR GenMix systems.
  • Lilly selected ABEC to support Basis of Design (BOD) engineering of the facility’s upstream and downstream processes utilizing ABEC’s CSR technology.
  • “ABEC is proud to be partnering with Lilly on this important project,” said Scott Pickering, ABEC CEO and Chairman.

Industrial Wastewater Treatment Global Market to 2028: Technological Advancements and Innovations in Wastewater Treatment Bolster Growth

Retrieved on: 
Tuesday, June 27, 2023
Urbanization, Food, L'Oréal, Temperature, Vegetable, Government, BOD, Water, Knowledge, Meat, Nestlé, Environment, Water resources, Population growth, Sewage treatment, Bottled water

DUBLIN, June 27, 2023 /PRNewswire/ -- The "Industrial Wastewater Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 27, 2023 /PRNewswire/ -- The "Industrial Wastewater Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global industrial wastewater treatment market is anticipated to develop rapidly in the forecast period, 2023-2028.
  • Industrial wastewater is water discarded, which is dissolved and suspended in water, usually during the industrial manufacturing process.
  • Consequently, to control the water crisis, there is a development of industrial wastewater management techniques.

NCSBN Selects Philip Dickison as New CEO

Retrieved on: 
Tuesday, May 23, 2023
Storm, FRE, Emergency medical responder levels by U.S. state, Reed Elsevier, Inc. v. Muchnick, National Council of State Boards of Nursing, Dickison, EMT, MSM, Licensure, Elsevier, Strategic planning, Doctor of Philosophy, Emergency medical technician, Certification, CSAC, Psychometrics, National Council, Evaluation, BOD, NCSBN, Gulf War, National Register of Historic Places, RN, Air force, Health, United States Department of the Air Force, Nursing, Management

Chicago, May 23, 2023 (GLOBE NEWSWIRE) -- Today, The National Council of State Boards of Nursing (NCSBN®) Board of Directors (BOD), has named Philip Dickison, PhD, RN, to succeed retiring CEO David Benton.

Key Points: 
  • Chicago, May 23, 2023 (GLOBE NEWSWIRE) -- Today, The National Council of State Boards of Nursing (NCSBN®) Board of Directors (BOD), has named Philip Dickison, PhD, RN, to succeed retiring CEO David Benton.
  • Dickison assumes duties as CEO on Oct. 1, 2023.
  • Dickison currently serves as NCSBN’s chief operating officer (COO), a post he has held since 2017.
  • In that capacity, he has traveled extensively representing NCSBN across the globe.

Medartis shareholders approve all proposals at the AGM 2023

Retrieved on: 
Friday, April 21, 2023
Human resources, Mass meeting, Assembly, Annual, AGM, Annual general meeting, BOD, Executive Committee, Swiss Code of Obligations, Central Executive Committee of the Pakistan Peoples Party, CHF, Compensated emancipation, Management, Basel

The shareholders granted discharge to the members of the Board of Directors (BOD) for their activities in the business year 2022.

Key Points: 
  • The shareholders granted discharge to the members of the Board of Directors (BOD) for their activities in the business year 2022.
  • In three separate votes, the shareholders approved the maximum total remuneration of the Board of Directors from the AGM 2023 to the AGM 2024 and the maximum total remuneration of the Executive Committee.
  • Shareholders approved a number of changes to Medartis' Articles of Association to implement new provisions of the Swiss Code of Obligations that came into force on 1 January 2023.
  • A detailed list of all resolutions and the voting distribution of the AGM 2023 can be found under the following link on the Medartis website.

Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors

Retrieved on: 
Wednesday, April 12, 2023
Janssen Pharmaceuticals, University, Prostate cancer, Johnson & Johnson, Cancer, Janssen, Barkat Pharmaceutical Group, Immunotherapy, Pulmonary hypertension, Retirement, Acquisition, BOD, Growth, Catholic University of Leuven (1834–1968), Autoimmunity, Pharmaceutical industry, Actelion

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD).

Key Points: 
  • BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today the appointment of industry veteran Patrick Verheyen to its board of directors (BOD).
  • Mr. Verheyen brings to Cue Biopharma more than 35-years of experience facilitating pipeline growth and innovation programs at Janssen Pharmaceutical Companies of Johnson and Johnson.
  • Cue Biopharma’s platform technology and drug product candidates represent a unique targeted approach to the treatment of cancer and autoimmune diseases.
  • Mr. Verheyen earned his master’s degree in bioengineering at the University of Leuven, Flanders, Belgium.

SM Entertainment Holds 28th Annual General Meeting of Shareholders and the New Board Appoints Cheol-hyuk Jang as CEO

Retrieved on: 
Friday, March 31, 2023
KRW, Executive, IR, Kakao Entertainment, B2B, PwC, Korea University Business School, EVP, Peter, Registered, AGM, AOI, Article, Confidentiality, Accounting, Inside director, Fan, Trust, Acquisition, SM, BOD, Vii, CFO, KPMG, SM Entertainment, Company secretary, Holding company, Management, Mobile phone

SEOUL, South Korea, March 31, 2023 /PRNewswire/ -- On Friday, SM Entertainment ("SM" or the "Company") (KRX:041510) announced that all agendas proposed by the Company's Board of Directors(BOD) were approved by its shareholders at the 28th Annual General Meeting of Shareholders(AGM) held at SM headquarter in Seongsu-dong, Seoul. With this, the foundation has been laid for implementing the SM 3.0 strategy, an essential element for the Company to move forward to a fan and shareholder-centered global entertainment company. 

Key Points: 
  • SEOUL, South Korea, March 31, 2023 /PRNewswire/ -- On Friday, SM Entertainment ("SM" or the "Company") (KRX:041510) announced that all agendas proposed by the Company's Board of Directors(BOD) were approved by its shareholders at the 28th Annual General Meeting of Shareholders(AGM) held at SM headquarter in Seongsu-dong, Seoul.
  • First, shareholders voted to approve the proposed cash dividend payment of KRW 1,200 per share as proposed.
  • Following the AGM, the new BOD called for Board of Directors meeting and appointed Inside Director Cheol-hyuk Jang as its new CEO.
  • Jang stated, "I feel a great responsibility to assume the position as a CEO when SM is about to take a big leap forward with SM 3.0."